20/20 Biolabs Inc (NASDAQ:AIDX) Sees Large Growth in Short Interest

20/20 Biolabs Inc (NASDAQ:AIDX – Get Free Report) was the recipient of a large growth in short interest in the month of April. As of April 30th, there was short interest totaling 33,116 shares, a growth of 74.8% from the April 15th total of 18,940 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average daily volume of 61,031 shares, the days-to-cover ratio is currently 0.5 days.

20/20 Biolabs Stock Down 1.5%

20/20 Biolabs stock opened at $1.32 on Tuesday. The firm has a 50 day simple moving average of $1.83. 20/20 Biolabs has a 1-year low of $1.26 and a 1-year high of $50.00.

Get 20/20 Biolabs alerts:

20/20 Biolabs (NASDAQ:AIDX – Get Free Report) last posted its earnings results on Tuesday, March 31st. The company reported ($0.26) earnings per share (EPS) for the quarter. The business had revenue of $0.54 million during the quarter.

Analyst Ratings Changes

Several analysts have issued reports on the company. Weiss Ratings assumed coverage on 20/20 Biolabs in a research note on Thursday. They issued a “sell (e-)” rating on the stock. Maxim Group began coverage on 20/20 Biolabs in a report on Monday, May 11th. They issued a “buy” rating and a $5.00 price objective for the company. Finally, Wall Street Zen upgraded 20/20 Biolabs to a “hold” rating in a research note on Saturday, March 14th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $5.00.

Get Our Latest Stock Analysis on 20/20 Biolabs

About 20/20 Biolabs

(Get Free Report)

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.

Featured Stories

• Five stocks we like better than 20/20 Biolabs
• Why Applied Optoelectronics Stock May Be Near a Turning Point
• From High-Yield to High-Growth: 3 Stocks Boosting Dividends
• Is Everspin Technologies the Next AI Edge Breakout?
• 5 Robotics Stocks to Watch as Physical AI Builds Momentum

Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.